Blinded interpretation of study results can feasibly and effectively diminish interpretation bias

详细信息    查看全文

• 作者：Teppo L.N. Jä ; rvinen^a ; ^b ; Raine Sihvonen^c ; Mohit Bhandari^d ; ^e ; Sheila Sprague^d ; ^e ; Antti Malmivaara^f ; Mika Paavola^a ; Holger J. Schü ; nemann^d ; ^g ; Gordon H. Guyatt^d ; ^g ; ^{guyatt@mcmaster.ca" class="auth_mail}
• 关键词：Bias ; Data interpretations ; Double-blind method ; Drug evaluation/methods ; Randomized controlled trials as topic/methods ; Research design
• 刊名：Journal of Clinical Epidemiology
• 出版年：July 2014
• 年：2014
• 卷：67
• 期：7
• 页码：769-772
• 全文大小：146 K

文摘

Controversial and misleading interpretation of data from randomized trials is common. How to avoid misleading interpretation has received little attention. Herein, we describe two applications of an approach that involves blinded interpretation of the results by study investigators.

Study Design and Settings

The approach involves developing two interpretations of the results on the basis of a blinded review of the primary outcome data (experimental treatment A compared with control treatment B). One interpretation assumes that A is the experimental intervention and another assumes that A is the control. After agreeing that there will be no further changes, the investigators record their decisions and sign the resulting document. The randomization code is then broken, the correct interpretation chosen, and the manuscript finalized. Review of the document by an external authority before finalization can provide another safeguard against interpretation bias.

Results

We found the blinded preparation of a summary of data interpretation described in this article practical, efficient, and useful.

Conclusions

Blinded data interpretation may decrease the frequency of misleading data interpretation. Widespread adoption of blinded data interpretation would be greatly facilitated were it added to the minimum set of recommendations outlining proper conduct of randomized controlled trials (eg, the Consolidated Standards of Reporting Trials statement).